Trial Profile
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jul 2014
Price :
$35
*
At a glance
- Drugs Gimatecan (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 07 Jun 2014 Status changed from discontinued to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 03 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.